Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the best possible (optimal) dose (effect versus adverse
events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement
surgery.